Literature DB >> 24797145

Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.

Mariya L Samoylova1, Jennifer L Dodge, Francis Y Yao, John Paul Roberts.   

Abstract

In the United States, there are significant geographic disparities in the time to transplantation for patients with hepatocellular carcinoma (HCC); it is possible that rapid transplantation contributes to higher rates of posttransplant HCC recurrence because there is insufficient time for the tumor biology to manifest. In this study, we compared HCC recurrence in rapid transplant patients and their slower transplant counterparts. We identified adult liver transplantation (LT) candidates in the Organ Procurement and Transplantation Network/United Network for Organ Sharing (UNOS) data set who were granted an initial exception for an HCC diagnosis between January 1, 2006 and September 30, 2010 and underwent transplantation in the same time window. Patients were followed until HCC recurrence, non-HCC-related death, or last follow-up. The cumulative incidence of HCC recurrence was compared for patients waiting ≤ 120 days and patients waiting >120 days from an HCC exception to LT. The association between the risk of posttransplant recurrence and the wait time was further evaluated via competing risks regression with the Fine and Gray model. For 5002 LT recipients with HCC, the median wait time from an exception to LT was 77 days, and it varied from 30 to 169 days by UNOS region. The cumulative incidence of posttransplant HCC recurrence was 3.3% [95% confidence interval (CI) = 2.8%-3.8%] and 5.6% (95% CI = 5.0%-6.3%) within 1 and 2 years, respectively. The rate of observed recurrence within 1 year of transplantation was significantly lower for patients waiting >120 days versus patients waiting ≤ 120 days (2.2% versus 3.9%, P = 0.002); however, the difference did not persist at 2 years (5.0% versus 5.9%, P = 0.09). After we accounted for clinical factors, the HCC recurrence risk was reduced by 40% for patients waiting >120 days (subhazard ratio = 0.6, P = 0.005). In conclusion, the risk of HCC recurrence within the first year after transplantation may be lessened by the institution of a mandatory waiting time after an exception is granted.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24797145      PMCID: PMC4394747          DOI: 10.1002/lt.23902

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  39 in total

1.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

2.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

3.  Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma.

Authors:  S D Chao; J P Roberts; M Farr; F Y Yao
Journal:  Am J Transplant       Date:  2007-04-08       Impact factor: 8.086

Review 4.  Patient selection in an era of donor liver shortage: current US policy.

Authors:  Russell H Wiesner
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-01

5.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

6.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

7.  Intention to treat survival following liver transplantation for hepatocellular carcinoma within a donor service area.

Authors:  Kevin P Charpentier; Yee Lee Cheah; Jason T Machan; Tom Miner; Paul Morrissey; Anthony Monaco
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

9.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  20 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.

Authors:  Silvio Nadalin; Lara Genedy; Alfred Königsrainer
Journal:  Recent Results Cancer Res       Date:  2021

Review 3.  Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.

Authors:  Trevor W Reichman; Chandra S Bhati; Narendra R Battula
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 4.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

5.   Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.

Authors:  Monika Sarkar; Jennifer L Dodge; John P Roberts; Norah Terrault; Francis Yao; Neil Mehta
Journal:  Ann Hepatol       Date:  2016 Jul-Aug       Impact factor: 2.400

6.  Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Parsia A Vagefi; Jennifer L Dodge; Francis Y Yao; John P Roberts
Journal:  Liver Transpl       Date:  2015-02       Impact factor: 5.799

7.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

8.  Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".

Authors:  Neil Mehta; Julie Heimbach; David Lee; Jennifer L Dodge; Denise Harnois; Justin Burns; William Sanchez; John P Roberts; Francis Y Yao
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

Review 9.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

10.  National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.

Authors:  Neil Mehta; Jennifer L Dodge; Joshua D Grab; Francis Y Yao
Journal:  Hepatology       Date:  2019-10-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.